|  | Alternative Medicine | Breathwork

COVID-19 and the Lungs: Impact on Respiratory Health

SARS-CoV-2 primarily targets the respiratory tract via ACE2 receptors abundant on airway and alveolar epithelial cells. The resulting pulmonary pathology ranges from mild inflammation to life-threatening respiratory failure, with potential long-term sequelae.

Pathophysiology: Step-by-Step

  1. Viral entry & replication: Spike protein binds ACE2 on type II alveolar pneumocytes, ciliated airway cells, nasal epithelium. Viral replication triggers cell death and innate immune activation.
  2. Innate immune response & inflammation: Infected cells release cytokines/chemokines (IL-6, TNF-α, IFN-γ, CCL2) recruiting neutrophils, monocytes, macrophages. In severe cases, "cytokine storm" causes systemic hyperinflammation.
  3. Alveolar damage & impaired gas exchange: Type II pneumocyte loss reduces surfactant → alveolar collapse. Inflammatory exudate (fluid, protein, cells) fills alveoli → hypoxemia. Diffuse alveolar damage (DAD) is the histologic hallmark of severe COVID pneumonia.
  4. Progression to ARDS: Acute Respiratory Distress Syndrome—bilateral infiltrates, severe hypoxemia (PaO2/FiO2 <300), non-cardiogenic pulmonary edema. Requires high-flow oxygen, NIV, or mechanical ventilation. Prone positioning improves V/Q matching.
  5. Vascular complications: Endothelialitis, microthrombi, pulmonary embolism, coagulopathy (elevated D-dimer). Anticoagulation is standard in hospitalized patients.
  6. Fibrosis & scarring: Post-ARDS, organizing pneumonia and fibrosis may develop—reticulation, traction bronchiectasis, honeycombing on CT. Can cause permanent reduction in diffusion capacity (DLCO) and exercise limitation.
  7. Long-term pulmonary sequelae (Long COVID): Persistent dyspnea, reduced exercise tolerance, cough, fatigue, DLCO impairment. Mechanisms: residual fibrosis, vascular dysfunction, autonomic dysregulation, deconditioning.

Clinical Spectrum

  • Mild: Upper respiratory symptoms only; no pneumonia on imaging.
  • Moderate: Pneumonia on imaging; SpO2 ≥94% on room air.
  • Severe: SpO2 <94%, RR >30, lung infiltrates >50%.
  • Critical: ARDS, septic shock, multi-organ failure.

Protection & Mitigation

  • Vaccination: Reduces severe pneumonia, hospitalization, death by >90% (waning vs. infection, durable vs. severe). Updated boosters critical.
  • Early antivirals: Paxlovid within 5 days reduces progression to severe disease.
  • Masks, ventilation, distancing: Reduce inoculum and transmission.
  • Post-COVID pulmonary rehab: Improves exercise capacity, dyspnea, quality of life.

While most recover fully, COVID-19 can leave lasting respiratory impairment. Prevention, early treatment, and rehabilitation are key to preserving lung health.

Breathwork - Related Articles